AMJC news story
Early evidence related to the use of chimeric antigen receptor T-cell (CAR-T) and natural killer-cell (CAR-NK) therapies suggests they hold promise as potential treatments for chronic hepatitis B virus (HBV) and HIV infections.
CAR therapies were originally developed to treat cancer, and they have proven successful at treating some types of hematologic malignancies. That success led scientists to investigate other possible applications for the technology.
Read the full news story here.
Source : AMJC
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.